What Opocrin does

Opocrin S.p.A. is an Italian privately held pharmaceutical company founded in 1964 by pharmacologist Prof. Pietro Bianchini in Modena, Italy, and still controlled by the Saetti-Bianchini family. The company specializes in the research, manufacturing, and commercialization of active pharmaceutical ingredients (APIs) and complex molecules derived from biological sources, with a particular focus on heparin and heparin derivatives extracted from porcine intestinal mucosa. Its portfolio spans five categories: heparins (heparin sodium, heparin calcium, parnaparin sodium), glycosaminoglycans (sulodexide, mesoglycan, heparinoid variants), iron complexes (iron sucrose, ferric carboxymaltose), pulmonary surfactants (poractant alpha), and ancillary products (catalase, collagen gel, ferric protein, heparan sulphate). Core technology centers on proprietary purification processes for virus and prion removal and integrated depolymerization techniques that yield novel heparin fractions with new biological activities, several of which are protected by granted patents.

The company operates four manufacturing facilities — three in Italy (Corlo/Formigine, Nonantola, Trino) and one in Mexico (PC Biologics in Valle de Santiago) — plus an R&D centre in Corlo and a commercial office in the Shanghai Pilot Free Trade Zone. Its commercial model is B2B enterprise: APIs and contract manufacturing services are sold directly to pharmaceutical multinationals and through qualified local distributors across more than 50 countries, with raw materials procured directly in the USA, Europe, and China. Revenue is generated through API product sales, contract manufacturing (process and analytical method development plus regulatory support), and licensing/technology transfer of proprietary heparin derivative processes; pricing is not publicly disclosed. Regulatory coverage includes AIFA certification for all three Italian plants, FDA Foreign Drug Manufacturer status, ISO 14001:2015, and ISO 45001:2023, with Top Employer Italy 2026 recognition.

Opocrin functions within the broader Opocrin Group, which also encompasses Omikron Italia S.r.l., a sister entity developing finished therapeutic products in vascular, ocular, and metabolic indications. The group's stated strategy emphasizes continuous R&D investment, lifecycle management from raw material to commercialization, expansion of non-anticoagulant heparin derivatives into new therapeutic areas, and inorganic growth — exemplified by the April 2020 acquisition of Laboratori Derivati Organici. Operating geographies span Europe (Italy, Spain), North America (USA), Asia Pacific (China), and Latin America (Mexico), with a claimed global market leadership position in heparin derivative APIs.

Name

Opocrin

Legal name

Opocrin S.p.A.

Website

https://opocrin.it

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

101–250 employees

Short description

Opocrin is a privately held Italian pharmaceutical company that researches, manufactures, and commercializes active pharmaceutical ingredients specializing in heparin and derivatives extracted from biological sources, supplying pharmaceutical multinationals and distributors across more than 50 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Active Ingredients

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Active pharmaceutical ingredients
• Heparin derivatives
• Low molecular weight heparin
• Pharmaceutical API manufacturing
• Heparinoid compounds

Headquarters

HQ city

Formigine

HQ country

Italy

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (API) Manufacturing and Sales: Research, production and commercialization of pharmaceutical active ingredients and complex molecules, specializing in heparins and derivatives. Revenue generated from supplying APIs for clinical trials and commercial production to pharmaceutical partners.
2. Contract Manufacturing Services: Contract manufacturing services including development and validation of industrial processes, development and validation of analytical methods, and regulatory support for pharmaceutical partners.
3. Licensing and Technology Transfer: Licensing of proprietary technologies and processes to pharmaceutical partners for production of heparin derivatives and other complex molecules.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Opocrin S.p.A. researches, manufactures, and commercializes active pharmaceutical ingredients (APIs), with a world-leading focus on heparin derivatives such as heparin sodium, heparin calcium, LMWH parnaparin sodium, sulodexide, and mesoglycan. The company also produces iron-based APIs, surfactants, and biological actives for pharmaceutical multinationals worldwide. Opocrin operates its own manufacturing plants in Italy and Mexico and sells in more than 50 countries.

Product overview

Opocrin is a world leader in the research, production, and marketing of pharmaceutical active ingredients and complex molecules, specialising in heparins and derivatives. The product portfolio comprises five main categories: (1) Heparins including Heparin sodium, Heparin calcium, and Parnaparin sodium (low-molecular-weight heparin) used for anticoagulant and antithrombotic therapies; (2) Glycosaminoglycans including Sulodexide, Mesoglycan, Heparinoid (JP), and Heparinoid (High-Activity) for vascular and inflammatory treatments; (3) Iron complexes including Iron sucrose and Ferric carboxymaltose for iron deficiency treatment; (4) Pulmonary surfactants with Poractant alpha for respiratory distress syndrome in premature infants; and (5) Other products including Catalase for dermatological use, Collagen gel, Ferric protein, and Heparan sulphate for non-pharmaceutical applications. The company operates as a contract manufacturer offering industrial process development, analytical method development and validation, and regulatory support services.

Differentiator

Problem solved

Functional benefit

Products and services

• Heparin sodium Active pharmaceutical ingredient of heparin sodium used by pharmaceutical manufacturers as the foundational API for anticoagulant finished drug products.
• Heparin calcium Active pharmaceutical ingredient of heparin calcium supplied to pharmaceutical manufacturers for anticoagulant and related finished formulations.
• Parnaparin sodium (LMWH) Low molecular weight heparin active pharmaceutical ingredient (parnaparin sodium) produced via Opocrin's integrated depolymerization process, used by pharmaceutical manufacturers in anticoagulant and antithrombotic finished drug products.
• Sulodexide Glycosaminoglycan-derived active pharmaceutical ingredient (sulodexide) supplied by Opocrin for vascular and antithrombotic finished drug formulations manufactured by pharmaceutical companies.
• Mesoglycan Glycosaminoglycan-derived active pharmaceutical ingredient (mesoglycan) supplied by Opocrin for vascular and connective-tissue finished drug formulations manufactured by pharmaceutical companies.
• Heparinoid (JP) Heparinoid active pharmaceutical ingredient produced to Japanese pharmacopeia specifications, supplied to pharmaceutical manufacturers for finished heparinoid products in Japan and other regulated markets.
• Heparinoid (High-Activity) High-activity heparinoid active pharmaceutical ingredient produced by Opocrin for pharmaceutical manufacturers requiring higher potency heparinoid actives in finished formulations.
• Iron sucrose Intravenous iron active pharmaceutical ingredient (iron sucrose) supplied by Opocrin to pharmaceutical manufacturers for iron-deficiency anemia treatments.
• Ferric carboxymaltose Intravenous iron active pharmaceutical ingredient (ferric carboxymaltose) supplied by Opocrin to pharmaceutical manufacturers for next-generation iron-deficiency anemia treatments.
• Poractant alpha Surfactant active pharmaceutical ingredient (poractant alpha) supplied by Opocrin to pharmaceutical manufacturers for neonatal respiratory distress syndrome treatments.
• Catalase Biological active pharmaceutical ingredient (catalase) supplied by Opocrin for pharmaceutical and diagnostic applications.
• Collagen gel Biological active pharmaceutical ingredient (collagen gel) supplied by Opocrin for wound care, dermatological, and related pharmaceutical applications.
• Ferric protein Iron-containing protein active pharmaceutical ingredient supplied by Opocrin for pharmaceutical manufacturers producing iron supplementation therapies.
• Heparan sulphate Glycosaminoglycan-derived active pharmaceutical ingredient (heparan sulphate) supplied by Opocrin for research, diagnostic, and pharmaceutical applications.

Quantifiable outcome

• Global market leadership in heparin derivatives
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and important.

• Pharmaceutical MultinationalscoreStrategic or Co-development PartnerOpocrin has established solid strategic alliances with important pharmaceutical sector multinationals since 1964. These partnerships involve development of innovative products and supply of active pharmaceutical ingredients for clinical trials through to commercial production.
• Qualified Local DistributorscoreChannel Partner/ Reseller/ DistributorExport business developed in partnership with qualified local distributors to serve regional pharmaceutical markets and be closer to customers in various countries.
• Research Centers, Universities and Start-upsimportantStrategic or Co-development PartnerOpocrin collaborates with research centers, universities and start-ups to maintain an innovative approach with continuous improvement. Joint work on developing new molecules and generifying active pharmaceutical ingredients.
• Contract Manufacturing PartnersimportantImplementation/ SI/ Consulting PartnerOpocrin works closely with selected partners for development of new innovative products, managing projects from API supply for clinical trials to industrial-scale commercial production. Recent collaborations developed new heparin derivatives without anticoagulant activity opening new therapeutic areas.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Shenzhen Hepalink Pharmaceutical Group: Shenzhen Hepalink is the world's largest heparin API manufacturer, producing both standard heparin and LMWH APIs from porcine intestines. It directly competes with Opocrin on global heparin API supply, particularly into pharmaceutical multinationals, but at significantly greater scale and lower cost.
• Bioiberica: Bioiberica is a Spanish life-science company specializing in heparin APIs, glycosaminoglycans, and plasma-derived biologicals for human and animal health. It is one of the closest comparables to Opocrin, competing head-to-head in heparin derivatives and chondroitin/sulodexide-type specialty APIs.
• Nanjing King-Friend Biochemical Pharmaceutical: Nanjing King-Friend is a major Chinese heparin and LMWH API manufacturer with FDA-inspected facilities. It competes with Opocrin in the global heparin API market, particularly on standard heparin and enoxaparin-class LMWH products, with a cost advantage derived from Chinese raw-material proximity.
• Changshan Pharmaceutical (subsidiary of China Grand Pharmaceutical): Changshan Pharmaceutical is a major Chinese heparin and LMWH API producer, now part of China Grand Pharmaceutical. It is a direct peer in heparin API manufacturing, primarily competing on cost and volume in standard heparin and low-molecular-weight heparin APIs.

Broad incumbents

• Aspen Pharmacare: Aspen Pharmacare is a South African-headquartered multinational pharmaceutical company with a significant heparin and anticoagulant franchise alongside a broad specialty and generics portfolio. It overlaps with Opocrin in heparin API and finished-dose supply but operates as a much larger, geographically diversified player.
• Sanofi: Sanofi is a global pharmaceutical major with a substantial heparin and LMWH franchise (Lovenox/Clexane) and broader anticoagulant portfolio. While not a direct API competitor, Sanofi is one of the largest customers competing in the same downstream therapeutic markets and sets quality benchmarks that affect Opocrin's competitive positioning.
• Pfizer: Pfizer, through its Hospital and Injectables business, markets heparin and LMWH products globally and is both a major customer and competitor to API producers like Opocrin. Its scale and vertical integration in injectable anticoagulants frame the competitive landscape Opocrin operates in.

Regional players

• Yuhan Corporation: Yuhan is a leading South Korean pharmaceutical manufacturer with a heparin and LMWH business supplying both domestic and export markets. Comparable to Opocrin in API-and-finished-dose heparin capability, but primarily serves the Korean and broader Asian region.
• Mochida Pharmaceutical: Mochida Pharmaceutical is a Japanese specialty pharmaceutical company with a heparinoid franchise (topical heparinoid products) overlapping with Opocrin's glycosaminoglycan portfolio. It is a regional peer focused primarily on the Japanese market.

Emerging players

• Laboratorios Farmaceuticos Rovi: Rovi is a Spanish specialty pharmaceutical manufacturer with heparin and LMWH franchise capabilities across European markets. Comparable to Opocrin as a mid-sized European heparin and specialty API player, though Rovi has broader finished-dose and biosimilar activities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/opocrin-group

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opocrin